Advances in the treatment of second-line non-small-cell lung cancer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Treatment with third-generation chemotherapy agents improves survival and quality of life of patients with non-small-cell lung cancer (NSCLC). Despite these favorable outcomes, most patients receiving front-line therapy experience disease progression. The availability of many new novel agents with activity in NSCLC has prompted investigators to explore second-line chemotherapy options. For many years, docetaxel was the only approved agent for the second-line treatment of NSCLC. More recently, the multi-targeted antifolate pemetrexed has demonstrated activity in patients previously treated with chemotherapy with locally advanced or metastatic NSCLC. The findings of a phase III trial comparing pemetrexed to docetaxel led to the regulatory approval of pemetrexed as monotherapy for the second-line treatment of NSCLC. Several other novel therapies, including molecular targeting agents such as erlotinib, are under development in clinical trials in patients with NSCLC. One of these trials has subsequently led to the approval of erlotinib as second- or third-line therapy in advanced NSCLC.

Original languageEnglish
JournalLung Cancer
Volume50
Issue numberSUPPL. 1
DOIs
StatePublished - 2005

Fingerprint

Non-Small Cell Lung Carcinoma
Pemetrexed
docetaxel
Drug Therapy
Therapeutics
Folic Acid Antagonists
Disease Progression
Quality of Life
Research Personnel
Clinical Trials
Survival

Keywords

  • Antifolate
  • Lung cancer
  • Non-small-cell lung cancer
  • Pemetrexed
  • Thoracic cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Advances in the treatment of second-line non-small-cell lung cancer. / Hanna, Nasser.

In: Lung Cancer, Vol. 50, No. SUPPL. 1, 2005.

Research output: Contribution to journalArticle

@article{f2dcc2b1cea5460395349ebfea994672,
title = "Advances in the treatment of second-line non-small-cell lung cancer",
abstract = "Treatment with third-generation chemotherapy agents improves survival and quality of life of patients with non-small-cell lung cancer (NSCLC). Despite these favorable outcomes, most patients receiving front-line therapy experience disease progression. The availability of many new novel agents with activity in NSCLC has prompted investigators to explore second-line chemotherapy options. For many years, docetaxel was the only approved agent for the second-line treatment of NSCLC. More recently, the multi-targeted antifolate pemetrexed has demonstrated activity in patients previously treated with chemotherapy with locally advanced or metastatic NSCLC. The findings of a phase III trial comparing pemetrexed to docetaxel led to the regulatory approval of pemetrexed as monotherapy for the second-line treatment of NSCLC. Several other novel therapies, including molecular targeting agents such as erlotinib, are under development in clinical trials in patients with NSCLC. One of these trials has subsequently led to the approval of erlotinib as second- or third-line therapy in advanced NSCLC.",
keywords = "Antifolate, Lung cancer, Non-small-cell lung cancer, Pemetrexed, Thoracic cancer",
author = "Nasser Hanna",
year = "2005",
doi = "10.1016/S0169-5002(05)81554-5",
language = "English",
volume = "50",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Advances in the treatment of second-line non-small-cell lung cancer

AU - Hanna, Nasser

PY - 2005

Y1 - 2005

N2 - Treatment with third-generation chemotherapy agents improves survival and quality of life of patients with non-small-cell lung cancer (NSCLC). Despite these favorable outcomes, most patients receiving front-line therapy experience disease progression. The availability of many new novel agents with activity in NSCLC has prompted investigators to explore second-line chemotherapy options. For many years, docetaxel was the only approved agent for the second-line treatment of NSCLC. More recently, the multi-targeted antifolate pemetrexed has demonstrated activity in patients previously treated with chemotherapy with locally advanced or metastatic NSCLC. The findings of a phase III trial comparing pemetrexed to docetaxel led to the regulatory approval of pemetrexed as monotherapy for the second-line treatment of NSCLC. Several other novel therapies, including molecular targeting agents such as erlotinib, are under development in clinical trials in patients with NSCLC. One of these trials has subsequently led to the approval of erlotinib as second- or third-line therapy in advanced NSCLC.

AB - Treatment with third-generation chemotherapy agents improves survival and quality of life of patients with non-small-cell lung cancer (NSCLC). Despite these favorable outcomes, most patients receiving front-line therapy experience disease progression. The availability of many new novel agents with activity in NSCLC has prompted investigators to explore second-line chemotherapy options. For many years, docetaxel was the only approved agent for the second-line treatment of NSCLC. More recently, the multi-targeted antifolate pemetrexed has demonstrated activity in patients previously treated with chemotherapy with locally advanced or metastatic NSCLC. The findings of a phase III trial comparing pemetrexed to docetaxel led to the regulatory approval of pemetrexed as monotherapy for the second-line treatment of NSCLC. Several other novel therapies, including molecular targeting agents such as erlotinib, are under development in clinical trials in patients with NSCLC. One of these trials has subsequently led to the approval of erlotinib as second- or third-line therapy in advanced NSCLC.

KW - Antifolate

KW - Lung cancer

KW - Non-small-cell lung cancer

KW - Pemetrexed

KW - Thoracic cancer

UR - http://www.scopus.com/inward/record.url?scp=27744556762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744556762&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(05)81554-5

DO - 10.1016/S0169-5002(05)81554-5

M3 - Article

C2 - 16291425

AN - SCOPUS:27744556762

VL - 50

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - SUPPL. 1

ER -